What is the difference between fluticasone and mometasone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differences Between Fluticasone and Mometasone

Both fluticasone and mometasone are potent synthetic corticosteroids with similar efficacy profiles, but mometasone has once-daily dosing compared to fluticasone's typically twice-daily administration, which may improve patient adherence. 1

Pharmacological Properties

Receptor Binding and Specificity

  • Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 1.5 times that of fluticasone 2
  • However, mometasone is considerably less specific for the glucocorticoid receptor than fluticasone, showing significant activity at other nuclear steroid receptors 3:
    • Mometasone is a very potent agonist of the progesterone receptor
    • Mometasone displays partial agonist activity at the mineralocorticoid receptor
    • Fluticasone is more selective for the glucocorticoid receptor with minimal activity at other steroid receptors

Dosing Schedule

  • Fluticasone propionate is typically administered twice daily 1
  • Mometasone furoate is administered once daily, which may improve patient adherence 1

Pharmacokinetics

  • When switching between medications, fluticasone furoate requires a longer washout period (24 hours) compared to fluticasone propionate (6 hours) 1
  • Both medications have similar physicochemical properties and structure-activity relationships 4
  • Both have comparable systemic bioavailability when administered intranasally 4

Clinical Efficacy

Asthma Treatment

  • In asthma management, both are effective inhaled corticosteroids (ICSs) and are considered first-line therapy for persistent asthma 5
  • Clinical trials have shown that mometasone furoate 400 mcg twice daily is therapeutically equivalent to fluticasone propionate 500 mcg twice daily in patients with moderate-to-severe persistent asthma 6
  • A dose of 200 mcg twice daily of mometasone provides clinical benefit comparable to 250 mcg twice daily of fluticasone 7

Allergic Rhinitis Treatment

  • For allergic rhinitis, both medications effectively control symptoms 8
  • In perennial rhinitis treatment, once-daily mometasone furoate 200 mcg was found to be at least as effective as once-daily fluticasone propionate 200 mcg 8
  • Both medications showed similar percent reductions from baseline in nasal symptom scores (37% for mometasone and 39% for fluticasone) 8

Obstructive Sleep Apnea

  • Both medications have shown benefits in patients with obstructive sleep apnea, particularly those with rhinitis and snoring 5
  • Intranasal fluticasone and mometasone both can reduce the Apnea-Hypopnea Index (AHI) in patients with OSA 5

Safety Profile

Side Effects

  • Both medications have similar safety profiles when used at recommended doses 1
  • Neither significantly impacts bone mineral density or shows clinically meaningful HPA axis suppression at standard doses 1
  • Local side effects such as nasal irritation and epistaxis are rare with both medications 1
  • The incidence of oral candidiasis appears similar between equivalent doses of both medications 7

Practical Considerations

Formulations

  • Both are available in various formulations including nasal sprays and inhalers
  • Mometasone furoate is available in a dry powder inhaler (ASMANEX TWISTHALER) 2
  • Fluticasone is available in both propionate and furoate forms 1

Patient Selection

  • For patients requiring once-daily dosing to improve adherence, mometasone may be preferred 1
  • For patients with conditions where progesterone or mineralocorticoid activity might be concerning, fluticasone may be preferred due to its greater receptor specificity 3

In summary, while both medications are effective corticosteroids with similar efficacy profiles, the choice between them may depend on dosing preference, specific formulation needs, and consideration of their slightly different receptor activity profiles.

References

Guideline

Corticosteroid Treatment Options

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2001

Research

Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.